Yokogawa Electric Corporation (YOKEY)

Inozyme Pharma Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	176,097	188,754	139,884	121,438	117,687	102,916
Cash & Short-Term Investments	176,097	188,754	139,884	121,438	117,687	102,916
Cash Growth	20.78%	34.94%	15.19%	3.19%	14.35%	1.37%
Receivables	218,569	146,571	150,567	137,866	122,869	183,711
Inventory	54,238	50,927	54,714	48,405	43,004	35,730
Other Current Assets	28,241	110,061	110,008	89,552	80,635	22,954
Total Current Assets	477,145	496,313	455,173	397,261	364,195	345,311
Property, Plant & Equipment	86,771	87,732	91,038	87,559	86,943	84,579
Long-Term Investments	65,187	70,624	72,361	76,360	59,212	56,641
Goodwill	8,017	6,563	5,971	14,614	12,378	4,247
Other Intangible Assets	47,654	46,505	37,796	33,920	25,938	22,055
Long-Term Deferred Tax Assets	-	10,547	10,526	8,921	7,154	6,246
Other Long-Term Assets	16,939	1	1	2	2	2
Total Assets	701,713	718,285	672,866	618,637	555,822	519,081
Accounts Payable	31,762	42,239	41,475	41,324	36,709	34,720
Accrued Expenses	11,459	22,526	23,539	20,776	17,127	16,228
Short-Term Debt	108	327	295	45,475	21,576	26,921
Current Portion of Leases	-	2,584	2,780	2,219	2,758	2,183
Current Income Taxes Payable	9,536	34,174	31,069	25,213	24,972	22,452
Other Current Liabilities	75,252	95,934	87,376	78,090	74,050	66,489
Total Current Liabilities	187,806	197,784	186,534	213,097	177,192	168,993
Long-Term Debt	24,022	24,025	24,000	4,087	24,095	20,000
Long-Term Leases	-	7,115	5,808	5,292	5,619	5,544
Long-Term Deferred Tax Liabilities	-	4,916	3,864	2,519	2,077	3,288
Other Long-Term Liabilities	10,714	1,999	1,851	1,736	1,797	2,113
Total Liabilities	229,458	242,565	228,105	231,812	215,467	204,311
Common Stock	43,401	43,401	43,401	43,401	43,401	43,401
Additional Paid-In Capital	54,575	54,575	54,464	54,392	54,392	54,392
Retained Earnings	350,219	342,573	303,979	251,277	221,446	209,240
Treasury Stock	-34,681	-23,251	-19,357	-1,410	-1,407	-1,404
Comprehensive Income & Other	49,987	50,557	54,154	31,965	15,754	2,694
Total Common Equity	463,501	467,855	436,641	379,625	333,586	308,323
Minority Interest	8,754	7,865	8,120	7,200	6,769	6,447
Shareholders' Equity	472,255	475,720	444,761	386,825	340,355	314,770
Total Liabilities & Equity	701,713	718,285	672,866	618,637	555,822	519,081
Total Debt	24,130	34,051	32,883	57,073	54,048	54,648
Net Cash (Debt)	151,967	154,703	107,001	64,365	63,639	48,268
Net Cash Growth	24.95%	44.58%	66.24%	1.14%	31.85%	14.70%
Net Cash Per Share	586.37	594.81	407.33	241.13	238.41	180.82
Filing Date Shares Outstanding	255.05	255.71	260.15	266.93	266.93	266.93
Total Common Shares Outstanding	255.05	258.86	260.15	266.93	266.93	266.93
Working Capital	289,339	298,529	268,639	184,164	187,003	176,318
Book Value Per Share	1817.33	1807.37	1678.42	1422.19	1249.71	1155.06
Tangible Book Value	407,830	414,787	392,874	331,091	295,270	282,021
Tangible Book Value Per Share	1599.05	1602.36	1510.18	1240.37	1106.17	1056.53
Order Backlog	-	428,163	398,131	364,005	291,754	244,267

Updated Feb 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.